JNCE Key Statistics, Chart & Performance
The current stock price of JNCE is 1.88 USD. In the past month the price increased by 0.53%. In the past year, price decreased by -65.76%.
JNCE Latest News, Press Relases and Analysis
JNCE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.92 | 399.57B | ||
| AMGN | AMGEN INC | 15.08 | 177.64B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.40B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.24 | 115.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.96 | 75.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 898.27 | 60.52B | ||
| INSM | INSMED INC | N/A | 43.51B | ||
| NTRA | NATERA INC | N/A | 33.75B | ||
| BIIB | BIOGEN INC | 10.83 | 26.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.54 | 21.07B | ||
| INCY | INCYTE CORP | 15.97 | 20.13B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About JNCE
Company Profile
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 141 full-time employees. The company went IPO on 2017-01-26. The company is engaged in the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients through a biomarker-driven approach. Its pipeline is focused on product candidates to address PD-(L)1-inhibitor resistant and PD-(L)1 inhibitor sensitive tumors. Its program, JTX-8064, is a tumor-associated macrophage candidate from its Translational Science platform. JTX-8064 is a monoclonal antibody that binds to Leukocyte Immunoglobulin Like Receptor B2, (LILRB2), which is a cell surface receptor expressed on macrophages and other myeloid cells. JTX-1484 is a monoclonal antibody designed to block human Leukocyte Immunoglobulin Like Receptor B4, (LILRB4) on various myeloid cells. Its product candidate, vopratelimab, is a monoclonal antibody that binds to and activates T cell CO-Stimulator (ICOS). The company also develops JTX-1484 and JTX-2134 product candidates.
Company Info
JOUNCE THERAPEUTICS INC
780 Memorial Drive
Cambridge MASSACHUSETTS 02139 US
CEO: Richard Murray
Employees: 141
Phone: 18572593840.0
JOUNCE THERAPEUTICS INC / JNCE FAQ
What does JOUNCE THERAPEUTICS INC do?
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 141 full-time employees. The company went IPO on 2017-01-26. The company is engaged in the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients through a biomarker-driven approach. Its pipeline is focused on product candidates to address PD-(L)1-inhibitor resistant and PD-(L)1 inhibitor sensitive tumors. Its program, JTX-8064, is a tumor-associated macrophage candidate from its Translational Science platform. JTX-8064 is a monoclonal antibody that binds to Leukocyte Immunoglobulin Like Receptor B2, (LILRB2), which is a cell surface receptor expressed on macrophages and other myeloid cells. JTX-1484 is a monoclonal antibody designed to block human Leukocyte Immunoglobulin Like Receptor B4, (LILRB4) on various myeloid cells. Its product candidate, vopratelimab, is a monoclonal antibody that binds to and activates T cell CO-Stimulator (ICOS). The company also develops JTX-1484 and JTX-2134 product candidates.
What is the current price of JNCE stock?
The current stock price of JNCE is 1.88 USD. The price decreased by -2.59% in the last trading session.
What is the dividend status of JOUNCE THERAPEUTICS INC?
JNCE does not pay a dividend.
How is the ChartMill rating for JOUNCE THERAPEUTICS INC?
JNCE has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the employee count for JNCE stock?
JOUNCE THERAPEUTICS INC (JNCE) currently has 141 employees.
What is JOUNCE THERAPEUTICS INC worth?
JOUNCE THERAPEUTICS INC (JNCE) has a market capitalization of 98.95M USD. This makes JNCE a Micro Cap stock.
JNCE Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to JNCE. When comparing the yearly performance of all stocks, JNCE turns out to be only a medium performer in the overall market: it outperformed 50.11% of all stocks.
JNCE Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to JNCE. While JNCE seems to be doing ok healthwise, there are quite some concerns on its profitability.
JNCE Financial Highlights
Over the last trailing twelve months JNCE reported a non-GAAP Earnings per Share(EPS) of -0.99. The EPS increased by 46.2% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
JNCE Forecast & Estimates
13 analysts have analysed JNCE and the average price target is 1.65 USD. This implies a price decrease of -12.29% is expected in the next year compared to the current price of 1.88.
For the next year, analysts expect an EPS growth of -37.55% and a revenue growth -100% for JNCE